HHS Will Not Shy From Compliance Actions Arising From Part D’s Start-Up Phase, Leavitt Suggests
This article was originally published in The Pink Sheet Daily
Executive Summary
The department is currently investigating claims that some drug plans are not fulfilling their obligations, HHS Secretary Michael Leavitt says.
You may also be interested in...
Top Seven Pink Sheet Infographics Of 2023
A visual perspective on key regulatory topics in 2023, from clinical trial diversity to product approval trends and Medicare drug price negotiation.
Pink Sheet’s Top Seven Infographics Of 2022
From US drug pricing to Japan’s Sakigake expedited pathway, important regulatory developments and trends are easier to understand and track with Pink Sheet graphics.
Maureen Kenny, 1963-2022
Kenny, a mainstay of our publications for three decades, has passed away in London.